Updates in the Management of Diffuse Large B-Cell Lymphoma


In Partnership With

Yazan Samhouri, MD, discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape.

Yazan Samhouri, MD, a hematologist/oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network (AHN), discusses the latest advancements in the diffuse large B-cell lymphoma treatment landscape, including improving upon rituximab (Rituxan) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), the promise of bispecific antibodies, and more.


0:08 | There [have been] a lot of exciting changes in the last few years in diffuse large B-cell lymphoma. Usually in first-line settings, we still use chemoimmunotherapy as a standard of care, but we are always trying to improve that. R-CHOP is also usually a standard of care, but we’re [also] trying to improve that by adding novel therapies to it like bispecific T-cell engagers or monoclonal antibodies.

0:38 | There’s a clinical trial ongoing at AHN of lenalidomide in addition to R-CHOP compared with R-CHOP in the first-line. This treatment usually cures around 60% of the patients, but still there are 40% of patients that relapse or need further treatment. In the second-line setting, it depends when the patient relapses. If it's a late relapse, we usually go for salvage chemotherapy followed by an autologous stem cell transplantation. If it’s an earlier relapse, we think of chimeric antigen receptor [CAR] T-cell therapy based on the ZUMA-7 [NCT03391466] trial from last year.

1:22 | Bispecific T-cell engagers are promising, and we were all excited in the field about them and hearing about all the data for glofitamab and other bispecific T-cell engagers like epcoritamab [DuoBody®-CD3xCD20]. Those are exciting drugs because of the mechanism of action. They bind to CD3 on the T cells and bind to another target which is usually a CD20 on the lymphoma cells, and then they bring the T cells to the lymphoma cells to kill it and activate the immune system. They are a useful tool because they can be given in the community in contrast to CAR T-cell therapy which needs to be in a transplant or a CAR T center. This can expand access to a very useful treatment for our patients in this field.

2:12 | Also, the toxicity of these agents also seems similar to CAR T-cell therapy in terms of the cytokine release syndrome and neurotoxicity, but the rate of these toxicities are lower, and the grades are also lower.

Related Videos
Expert on GVHD
Expert on GVHD